FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072806284> ?p ?o ?g. }

• W2072806284 abstract "Dear editorAfter a century of allergen immunotherapy (AIT), for the first time, the Italian Agency for Drugs (AIFA [Agenzia italiana per il farmaco]) has just approved the full reimbursement (A class) for an AIT product, such as the 5-grass pollen tablet with the indication for treating allergic rhinitis (AR).On the other hand, AR represents a relevant health issue as the worldwide prevalence is approximately 20%.1 AR is sustained by an IgE-mediated inflammatory reaction that in turn induces typical symptom occurrence. Allergic inflammation is promoted by an allergen-specific defect of T-regulatory cells and a Th2 polarization.2 This impaired immune response characterizes the two main peculiarities of allergic reaction: systemic IgE production and nasal eosinophil infiltrate.3 AR has also a significant social burden both in terms of high costs and individual complaints, mainly negatively affecting quality of life. AR treatment is traditionally based on drug prescription, such as antihistamines and topical corticosteroids. However, the main limit of drug therapy is that it is essentially symptomatic and its efficacy quickly stops after suspension. On the contrary, AIT is the unique causal therapy of AR as it is able of inducing a long-lasting immunological and clinical tolerance toward the causal allergen.4 The mechanism of action of AIT is based on restored T-regulatory function and re-direction of immune response to a physiological Th1-oriented pathway.5 AIT consists of administering increasing doses of the causal allergen extract able to reduce allergic symptoms.6 There is strengthened evidence that AIT is effective and safe as recognized by the meta-analysis approach.7 At present, sublingual immunotherapy is commonly prescribed for AR patients as effective and well tolerated.The 5-grass pollen tablet according to a pre-co-seasonal course, has the indication for AR and/or conjunctivitis treatment in adult or pediatric (over 5 years) patients with severe symptoms as documented by two regulatory studies.8,9 AIFA’s decision of full-reimbursement for the 5-grass pollen tablet has been based on the qualified requirements of this product: allergen panel composition, effectiveness, safety, standardization, adequate dosage, and pharmaco-economic impact. First, sublingual tablets are composed of 5-grass pollens, belonging to Pooideae family (Dactylis glomerata, Anthoxanthum odoratum, Lolium perenne, Poa pratensis, and Phleum pratense). This 5-grass mixture is appropriate according to the production of pollen by the grasses as evidenced by phenological studies.10 In fact, the approach by phenology demonstrated that the different grasses yield their pollen in dissimilar times of the season in a specific geographical area in Italy and that some grasses, such as P. pratense, produce their pollen in periods out of the pollen peaks in the atmosphere, when patients have no more intense symptoms.10 Of course, the presence of a given grass species is closely related to symptom appearance in grass allergic patients. Thus, the 5-grass mixture extract has optimal characteristics to cover the whole grass pollination period, so assuring a clinical effectiveness for a large population of grass pollen allergic patients. In addition, it has been reported that the 5-grass pollen mixture has ideal immunological capability of inducing immunization in AR patients,11,12 considering that 5-grass pollen tablet contains a large array of allergens naturally occurring in the atmosphere, that trigger allergic symptoms. An immunological study demonstrated that in children living in the Mediterranean area the 5-grass mixture is more alike to natural grass exposure than P. pratense extract alone.13 Another interesting issue is the molecular aspect, because among the grass species there is a lot of differences in the amino acid sequence of the allergens from the group 1 and 5, as confirmed by a study of Moingeon et al14 who highlighted by mass spectrometry the different three-dimensional structure of these allergens between the Pooideae that results in a large number of epitopes that are not shared among the various species. Indeed, the characteristics of 5-grass pollen tablet have a clinical relevance as the administration of the 5-grass-pollen mixture allows to obtain quick effectiveness. In this regard, a study using the “Vienna chamber” model showed that 5-grass pollen tablet significantly reduced allergic symptoms after 7–30 days.15 Moreover, an economic evaluation stated that 5-grass pollen tablet is a cost-effective treatment in patients with grass pollen-induced seasonal AR.16 Another intriguing aspect is that its cost-effectiveness increases with the severity of AR symptoms as evidenced by a recent analysis concerning the higher clinical efficacy of the 5-grass pollen tablet treatment in patients with more severe AR.17 These outcomes should be thoroughly taken into consideration in the management of AR patients. It is also of note that 5-grass pollen tablet is a drug listed as treating grass allergy with AIT by the Canadian Drug Expert Committee.In conclusion, the AIFA decision about the full reimbursement of an AIT product for AR treatment has an outstanding importance for 5-grass pollen tablet, this fact provides a new consideration of AIT and paves the way to a new era in the centenary AIT history." @default.
• W2072806284 created "2016-06-24" @default.
• W2072806284 creator A5047558679 @default.
• W2072806284 date "2015-03-01" @default.
• W2072806284 modified "2023-09-26" @default.
• W2072806284 title "A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy" @default.
• W2072806284 cites W1481876993 @default.
• W2072806284 cites W1588096397 @default.
• W2072806284 cites W1966906126 @default.
• W2072806284 cites W1972499790 @default.
• W2072806284 cites W1973850474 @default.
• W2072806284 cites W1974283560 @default.
• W2072806284 cites W1992168461 @default.
• W2072806284 cites W2013737474 @default.
• W2072806284 cites W2028280773 @default.
• W2072806284 cites W2028884801 @default.
• W2072806284 cites W2032135071 @default.
• W2072806284 cites W2041142141 @default.
• W2072806284 cites W2093792384 @default.
• W2072806284 cites W2119223577 @default.
• W2072806284 cites W2128945530 @default.
• W2072806284 cites W2135705779 @default.
• W2072806284 cites W2414184110 @default.
• W2072806284 doi "https://doi.org/10.2147/jaa.s82077" @default.
• W2072806284 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4358645" @default.
• W2072806284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25834457" @default.
• W2072806284 hasPublicationYear "2015" @default.
• W2072806284 type Work @default.
• W2072806284 sameAs 2072806284 @default.
• W2072806284 citedByCount "3" @default.
• W2072806284 countsByYear W20728062842016 @default.
• W2072806284 countsByYear W20728062842017 @default.
• W2072806284 crossrefType "journal-article" @default.
• W2072806284 hasAuthorship W2072806284A5047558679 @default.
• W2072806284 hasBestOaLocation W20728062841 @default.
• W2072806284 hasConcept C141105273 @default.
• W2072806284 hasConcept C159654299 @default.
• W2072806284 hasConcept C203014093 @default.
• W2072806284 hasConcept C207480886 @default.
• W2072806284 hasConcept C2776042228 @default.
• W2072806284 hasConcept C2777037409 @default.
• W2072806284 hasConcept C2777701055 @default.
• W2072806284 hasConcept C2779787640 @default.
• W2072806284 hasConcept C2780510475 @default.
• W2072806284 hasConcept C2780870513 @default.
• W2072806284 hasConcept C71924100 @default.
• W2072806284 hasConcept C8891405 @default.
• W2072806284 hasConceptScore W2072806284C141105273 @default.
• W2072806284 hasConceptScore W2072806284C159654299 @default.
• W2072806284 hasConceptScore W2072806284C203014093 @default.
• W2072806284 hasConceptScore W2072806284C207480886 @default.
• W2072806284 hasConceptScore W2072806284C2776042228 @default.
• W2072806284 hasConceptScore W2072806284C2777037409 @default.
• W2072806284 hasConceptScore W2072806284C2777701055 @default.
• W2072806284 hasConceptScore W2072806284C2779787640 @default.
• W2072806284 hasConceptScore W2072806284C2780510475 @default.
• W2072806284 hasConceptScore W2072806284C2780870513 @default.
• W2072806284 hasConceptScore W2072806284C71924100 @default.
• W2072806284 hasConceptScore W2072806284C8891405 @default.
• W2072806284 hasLocation W20728062841 @default.
• W2072806284 hasLocation W20728062842 @default.
• W2072806284 hasLocation W20728062843 @default.
• W2072806284 hasLocation W20728062844 @default.
• W2072806284 hasOpenAccess W2072806284 @default.
• W2072806284 hasPrimaryLocation W20728062841 @default.
• W2072806284 hasRelatedWork W1994878904 @default.
• W2072806284 hasRelatedWork W2014171282 @default.
• W2072806284 hasRelatedWork W2021321948 @default.
• W2072806284 hasRelatedWork W2022883841 @default.
• W2072806284 hasRelatedWork W2066871437 @default.
• W2072806284 hasRelatedWork W2088096170 @default.
• W2072806284 hasRelatedWork W2129356951 @default.
• W2072806284 hasRelatedWork W2398503381 @default.
• W2072806284 hasRelatedWork W2735006218 @default.
• W2072806284 hasRelatedWork W4254770499 @default.
• W2072806284 isParatext "false" @default.
• W2072806284 isRetracted "false" @default.
• W2072806284 magId "2072806284" @default.
• W2072806284 workType "article" @default.